<DOC>
	<DOCNO>NCT02794207</DOCNO>
	<brief_summary>The primary objective study identify outcome related management neutropenia important child AML caregiver . Patients complete treatment AML caregiver interview order well understand impact neutropenia management child AML family . The primary outcome interview identify patient-centered outcome relate neutropenia management include subsequent comparative-effectiveness analysis . Investigators use data develop structure survey administration prospectively identify patient subsequent study .</brief_summary>
	<brief_title>Home Away From Home - Descriptive Interviews ( Aim 2 )</brief_title>
	<detailed_description>Treatment pediatric acute myeloid leukemia ( AML ) involve intensive chemotherapy regimens result period profound neutropenia leave patient susceptible severe infectious complication . There little clinical data inform whether management neutropenia post AML chemotherapy occur outpatient inpatient set . Further , study conduct assess impact neutropenia management strategy quality life pediatric patient AML . Given infectious complication lead cause treatment related mortality among AML patient , important identify neutropenia management strategy lead best clinician- patient- identify outcome order improve care patient . This qualitative interview study person interview patient and/or caregiver perform . Participants patient 18 year age young diagnosis ( caregiver ) receive receive Induction II chemotherapy AML eight participate pediatric hospital across United States . Participants ( child caregiver ) interview effort develop survey capture patient- caregiver- identify outcome relate neutropenia management .</detailed_description>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<criteria>1 . To enrol study , patient must : A male female 8 23 year age Have diagnosis AML Be either within 612 month completion second course chemotherapy AML OR AML therapy 3 year 2 . To enrol study , caregiver must : A male female 18 year age old Be parent/legal guardian child meet inclusion criterion detail ( # 1 ) OR Be parent/legal guardian male female child young 8 year age AML within 612 month completion second course chemotherapy Be parent/legal guardian male female child young 8 year age AML AML therapy 3 year 3 . Parental/guardian informed consent , appropriate , child assent . 1 ) None</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>23 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Pediatric</keyword>
	<keyword>Cancer</keyword>
	<keyword>AML</keyword>
	<keyword>Qualitative Interview</keyword>
</DOC>